{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
Basel, 16 November 2005\line \line {\b Roche and Gilead end 
dispute on influenza drug Tamiflu} \line \line Strong commitment of both companies 
to further enhance collaboration\line \line Gilead and Roche today announced the 
companies have ended their dispute related to the companies\u8217? 1996 Development and License Agreement. 
Under the terms of the amended agreement, Roche and Gilead will establish a joint committee to oversee 
the coordination of global manufacturing \u8211? including the consideration of third party licenses for manufacturing 
\u8211? and a joint committee to coordinate the commercialization of Tamiflu for seasonal sales in the most 
important markets including the United States. Gilead will also have the option to co-promote Tamiflu 
in specialised areas in the United States.\line \line William M. Burns, CEO Roche 
Pharmaceuticals Division, commented: \u8220?The redefined agreement with Gilead is an important step. Together, 
Roche and Gilead will be able to focus their efforts even more on making sure that the needs for this 
medicine can be met, both for the treatment and prevention of seasonal influenza as well as for the 
worldwide stockpiling for pandemic plans.\u8221?\line \line \u8220?The global threat of a potential 
avian flu pandemic has challenged governments, public health officials and the pharmaceutical industry 
to join together in partnership for the purpose of establishing a comprehensive plan to combat this 
deadly disease. Beyond this threat, seasonal influenza outbreaks result in hundreds of thousands of 
deaths each year around the world. We have ended our dispute with Roche in an effort to work together, 
with the utmost diligence, to address this global public health need,\u8221? said John C. Martin, PhD, President 
and CEO, Gilead Sciences. \u8220?As the inventor and the company that devised the manufacturing process for 
Tamiflu, Gilead looks forward to partnering our expertise with that of Roche, serving as an additional 
resource to support this important product.\u8221?\line \line Roche has agreed to waive 
the pre-existing contractual cost of goods adjustments from all future royalty calculations. Gilead\u8217?s 
royalty on net sales of Tamiflu is unchanged and will range from 14 to 22 percent, depending on the 
volume of sales in each year. Based on actual sales for the first nine months of 2005 and estimated 
pandemic sales for the fourth quarter, Gilead anticipates receiving a blended royalty for Roche\u8217?s full 
year 2005 Tamiflu sales in the range of 18 to 19 percent. As a result, Roche will also pay Gilead 62.5 
million US dollars in retroactive royalty adjustments to account for the elimination of the cost of 
goods adjustment for 2004 and for the first three quarters of 2005. In addition, Gilead will retain 
18.2 million US dollars that had been paid by Roche under protest in respect of disputed royalty calculations 
for sales in the period from 2001 through 2003. \line \line {\b About 
Tamiflu} \line Tamiflu (oseltamivir), the only oral antiviral for the treatment and prevention 
of influenza A and B, was invented by Gilead and licensed to Roche in 1996. Tamiflu is designed to be 
active against all clinically relevant influenza viruses. When neuraminidase is inhibited, the virus 
is not able to spread to and infect other cells in the body. Key international research groups have 
demonstrated, using animal models of influenza, that Tamiflu is effective against the avian H5N1 strain 
circulating in the Far East. As a result, more governments are stockpiling Tamiflu, therefore Roche 
is expanding a collaborative production network to meet the increasing demand. So far, Roche has received 
and/or fulfilled orders from around 50 countries. The manufacturing process for Tamiflu is complex and 
lengthy. Additional information about Tamiflu is available on the Internet (http://www.roche.com/med_mbfstamiflu.pdf).\line \line {\b About 
Gilead} \line Gilead Sciences is a biopharmaceutical company that discovers, develops 
and commercializes innovative therapeutics in areas of unmet medical need. The company\u8217?s mission is 
to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in 
Foster City, California, Gilead has operations in North America, Europe and Australia. Additional information 
about Gilead Sciences is available on the Internet (www.gilead.com (http://www.gilead.com)).\line \line {\b About 
Roche} \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of 
innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, 
the Group contributes on a broad range of fronts to improving people\u8217?s health and quality of life. Roche 
is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a 
market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss 
francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 
65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, 
including majority ownership interests in Genentech and Chugai. Additional information about the Roche 
Group is available on the Internet (www.roche.com).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\line \line {\b Further 
information} \line - Roche Health-Kiosk, Influenza (http://www.health-kiosk.ch/start_grip.htm)\line - 
WHO \u8211? avian flu (http://www.who.int/mediacentre/factsheets/avian_influenza/en/)
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}